WOBURN, Mass., Oct. 9 Tandem Labs, a leading contractresearch organization (CRO) providing bioanalytical, immunoanalytical, andpharmacokinetic (PK)/pharmacodynamic (PD) services to the pharmaceuticalindustry, announced that it has acquired additional MDS SCIEX API 5000(TM) and4000(TM) LC/MS/MS systems for its New England facility in Woburn,Massachusetts. This acquisition doubles the facility's current triplequadrupole LC/MS/MS capacity, allowing it to better serve its clientelethrough this expansion in capacity.
"Tandem Labs acquired these additional instruments to further increase ourcapacity in the critical New England region," said Denis C.K. Lin, Ph.D.,president and CEO. "These assets will significantly enhance our reach withinthe drug discovery and development industry, particularly in Massachusetts aswell as other Northeast states."
The New England operation is focused upon providing rapid turnaround non-GLP discovery PK/PD services in addition to metabolite identification andbiomarker services. Combined with other advanced mass spectrometric platformsbeyond the triple quadrupoles, the New England facility also uses proprietaryinformatics to reduce the difficulty, complexity, and time-consuming nature ofdeveloping and launching a drug to market. DMDiscovery(TM) is a drugmetabolism technology that increases the productivity of drug metaboliteidentification and quantification. MarkerScan(TM) is a biomarker discovery andscreening process that efficiently identifies potential biomarkers that can beused to increase the understanding of disease, diagnosis, and predictivemodels as well as drug compound safety, efficacy, and side-effect profiles.
Tandem Labs has additional facilities in Utah and New Jersey; the Utahlocation focuses primarily on GLP bioanalytical services and discovery supportwhile the New Jersey location specializes in GLP-compliant bioanalysis onLC/MS/MS and immunoanalytical platforms.
About Tandem Labs
Tandem Labs is a leading CRO specializing in advanced mass spectrometry,immunoanalytical support, and PK/PD for the pharmaceutical/biotechnologyindustries in the United States and internationally. With more than 30LC/MS/MS instruments and 54,000-square-feet available, Tandem Labs exists toserve the needs of its clients. By applying scientific ingenuity, responsivecommunication, flexible client service, disciplined compliance, and acommitment to information technology, Tandem supports drug discovery anddevelopment by offering a comprehensive suite of customizable services thathelp clients reduce their overall time in bringing new medicines to market.For further information, contact: Denis Lin, Ph.D. President & CEO Tandem Labs (801) 293-2400 e-mail: [email protected]
Jean Pineault, M.S. Vice President, Sales & Marketing Tandem Labs (609) 228-0201 e-mail: [email protected]
SOURCE Tandem Labs